Agree that 1801 has huge potential. However, I'd be surprised if we see it fully developed as a BOT product. Once SB gets FDA approval and we have a growing revenue stream, BOT will finally be materially derisked to a certain extent. Vinnie and his crew are masters of getting a deal done with big pharma. Matt has never made a secret that a buyout by BP is the likely end goal. Further trials and research takes heaps of time and money and has inherent risk. If they can negotiate a deal that they feel fairly values the huge potential of 1801, and other products, whilst acknowledging the development costs and risks, they'll definitely get the deal done. Will be extremely interesting to see how it all unfolds. In Vinnie we trust
BOT Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)